Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
( Published online November 24 ) Rossignol P, Masson S, Barlera S et al (2015) Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials
Consider staying at your current dose for an additional 2-4 weeks if you experience: Persistent nausea or vomiting lasting more than 3 days Rapid weight loss exceeding 3-4 lbs per week Severe constipation or diarrhea Signs of dehydration Significant injection site reactions The goal is to reach the maintenance dose gradually
The average liraglutide steady state concentration (AUC/24) reached approximately 116 ng/mL in obese (BMI 30-40 kg/m2) subjects following administration of SAXENDA
Indian Journal of Pharmaceutical Education and Research Vol 53, Issue 2, 2019
US$ 28.67
US$ 25.23
US$ 25.78
